ESPR Q4 2019 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$519M

Q4 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$982,000-99.5% YoY

Gross Profit

-$37M-3793.5% margin

Operating Income

-$59M-6004.5% margin

Net Income

-$62M-6308.1% margin

EPS (Diluted)

$-2.26

QoQ Revenue Growth

+0.1%

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$50M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$214M

Total Liabilities

$194M

Stockholders' Equity

$20M

Cash & Equivalents

$166M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$982,000	$184M	-99.5%
Gross Profit	-$37M	$135M	-127.6%
Operating Income	-$59M	-$61M	+2.8%
Net Income	-$62M	-$60M	-3.2%

Revenue Segments

Ongoing Regulatory And Development Activities Revenue

$1M100%